Do analysts recommend CABR or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CABR or SPRC?

Caring Brands has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caring Brands N/A N/A -$6.28M -$0.74 N/A SciSparc $860K 3.51 -$12.18M N/A N/A

Is CABR or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Caring Brands N/A -1,153.12% -322.63% SciSparc N/A N/A N/A

Does the media refer more to CABR or SPRC?

In the previous week, SciSparc had 3 more articles in the media than Caring Brands. MarketBeat recorded 5 mentions for SciSparc and 2 mentions for Caring Brands. Caring Brands' average media sentiment score of 0.83 beat SciSparc's score of 0.30 indicating that Caring Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caring Brands 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SciSparc 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DARE or SPRC?

Dare Bioscience presently has a consensus target price of $12.00, indicating a potential upside of 1,564.36%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, DARE or SPRC?

SciSparc has lower revenue, but higher earnings than Dare Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 13.77 -$13.40M -$0.70 N/A SciSparc $860K 3.51 -$12.18M N/A N/A

Does the media prefer DARE or SPRC?

In the previous week, SciSparc had 2 more articles in the media than Dare Bioscience. MarketBeat recorded 5 mentions for SciSparc and 3 mentions for Dare Bioscience. SciSparc's average media sentiment score of 0.30 beat Dare Bioscience's score of -0.24 indicating that SciSparc is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SciSparc 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SPRC or MBRX?

Moleculin Biotech has a consensus price target of $3.00, suggesting a potential upside of 322.59%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, SPRC or MBRX?

SciSparc has higher revenue and earnings than Moleculin Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.51 -$12.18M N/A N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is SPRC or MBRX more profitable?

SciSparc's return on equity of 0.00% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Moleculin Biotech N/A -143.51% -24.53%

Does the media favor SPRC or MBRX?

In the previous week, Moleculin Biotech had 2 more articles in the media than SciSparc. MarketBeat recorded 7 mentions for Moleculin Biotech and 5 mentions for SciSparc. SciSparc's average media sentiment score of 0.30 beat Moleculin Biotech's score of 0.28 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SPRC or FNCH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, SPRC or FNCH?

SciSparc has higher revenue and earnings than Finch Therapeutics Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.51 -$12.18M N/A N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is SPRC or FNCH more profitable?

SciSparc's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts recommend SPRC or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, SPRC or ASBP?

SciSparc has higher revenue and earnings than Aspire Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.51 -$12.18M N/A N/A Aspire Biopharma $10K 1,241.80 -$24.48M -$69.62 N/A

Is SPRC or ASBP more profitable?

SciSparc has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Aspire Biopharma -11,362.21% N/A -177.59%

SciSparc (SPRC) Competitors

$5.29 +0.16 (+3.12%)

As of 09/4/2026 03:59 PM Eastern

Compare

SPRC vs. CABR, DARE, MBRX, FNCH, and ASBP

Should you buy SciSparc stock or one of its competitors? SciSparc's main competitors and comparable companies include Caring Brands (CABR), Dare Bioscience (DARE), Moleculin Biotech (MBRX), Finch Therapeutics Group (FNCH), and Aspire Biopharma (ASBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SciSparc compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, SciSparc had 3 more articles in the media than Caring Brands. MarketBeat recorded 5 mentions for SciSparc and 2 mentions for Caring Brands. Caring Brands' average media sentiment score of 0.83 beat SciSparc's score of 0.30 indicating that Caring Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caring Brands	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SciSparc	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SciSparc's return on equity of 0.00% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	-1,153.12%	-322.63%
SciSparc	N/A	N/A	N/A

25.1% of SciSparc shares are owned by institutional investors. 14.6% of Caring Brands shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Caring Brands has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A
SciSparc	$860K	3.51	-$12.18M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SciSparc beats Caring Brands on 5 of the 8 factors compared between the two stocks.

How does SciSparc compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

SciSparc has lower revenue, but higher earnings than Dare Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	13.77	-$13.40M	-$0.70	N/A
SciSparc	$860K	3.51	-$12.18M	N/A	N/A

Dare Bioscience has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, SciSparc had 2 more articles in the media than Dare Bioscience. MarketBeat recorded 5 mentions for SciSparc and 3 mentions for Dare Bioscience. SciSparc's average media sentiment score of 0.30 beat Dare Bioscience's score of -0.24 indicating that SciSparc is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SciSparc	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience presently has a consensus target price of $12.00, indicating a potential upside of 1,564.36%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. SciSparc's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
SciSparc	N/A	N/A	N/A

Summary

SciSparc beats Dare Bioscience on 8 of the 14 factors compared between the two stocks.

How does SciSparc compare to Moleculin Biotech?

SciSparc (NASDAQ:SPRC) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

25.1% of SciSparc shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Moleculin Biotech has a consensus price target of $3.00, suggesting a potential upside of 322.59%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Moleculin Biotech had 2 more articles in the media than SciSparc. MarketBeat recorded 7 mentions for Moleculin Biotech and 5 mentions for SciSparc. SciSparc's average media sentiment score of 0.30 beat Moleculin Biotech's score of 0.28 indicating that SciSparc is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

SciSparc's return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Moleculin Biotech	N/A	-143.51%	-24.53%

SciSparc has higher revenue and earnings than Moleculin Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.51	-$12.18M	N/A	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

SciSparc has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Summary

SciSparc beats Moleculin Biotech on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to Finch Therapeutics Group?

SciSparc (NASDAQ:SPRC) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

SciSparc has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

SciSparc has higher revenue and earnings than Finch Therapeutics Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.51	-$12.18M	N/A	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

In the previous week, SciSparc had 5 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 5 mentions for SciSparc and 0 mentions for Finch Therapeutics Group. SciSparc's average media sentiment score of 0.30 beat Finch Therapeutics Group's score of 0.00 indicating that SciSparc is being referred to more favorably in the media.

Company	Overall Sentiment
SciSparc	Neutral
Finch Therapeutics Group	Neutral

SciSparc's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Finch Therapeutics Group	N/A	-69.14%	-26.92%

25.1% of SciSparc shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SciSparc beats Finch Therapeutics Group on 9 of the 10 factors compared between the two stocks.

How does SciSparc compare to Aspire Biopharma?

SciSparc (NASDAQ:SPRC) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

25.1% of SciSparc shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, SciSparc had 5 more articles in the media than Aspire Biopharma. MarketBeat recorded 5 mentions for SciSparc and 0 mentions for Aspire Biopharma. SciSparc's average media sentiment score of 0.30 beat Aspire Biopharma's score of 0.00 indicating that SciSparc is being referred to more favorably in the media.

Company	Overall Sentiment
SciSparc	Neutral
Aspire Biopharma	Neutral

SciSparc has higher revenue and earnings than Aspire Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.51	-$12.18M	N/A	N/A
Aspire Biopharma	$10K	1,241.80	-$24.48M	-$69.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc has a beta of 2.81, suggesting that its share price is 181% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

SciSparc has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Aspire Biopharma	-11,362.21%	N/A	-177.59%

Summary

SciSparc beats Aspire Biopharma on 8 of the 10 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.99M	$12.25B	$7.25B	$12.92B
Dividend Yield	N/A	2.58%	2.53%	9.14%
P/E Ratio	N/A	792.20	273.54	25.43
Price / Sales	3.51	754.62	625.17	94.95
Price / Cash	N/A	90.26	77.08	52.44
Price / Book	0.41	12.47	12.85	6.17
Net Income	-$12.18M	$2.83B	$3.49B	$350.08M
7 Day Performance	-19.60%	4.03%	1.04%	-0.14%
1 Month Performance	-23.22%	6.29%	5.52%	1.02%
1 Year Performance	-73.64%	9.93%	24.39%	14.51%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	1.0825 of 5 stars	$5.29 +3.1%	N/A	-72.4%	$2.99M	$860K	N/A	4
CABR Caring Brands	0.4448 of 5 stars	$1.33 +3.5%	N/A	N/A	$13.32M	N/A	N/A	4
DARE Dare Bioscience	2.057 of 5 stars	$0.75 -8.5%	$10.00 +1,232.3%	-66.2%	$12.55M	$1.03M	N/A	30
MBRX Moleculin Biotech	3.2228 of 5 stars	$0.60 -1.8%	$22.00 +3,566.7%	-92.5%	$11.90M	N/A	N/A	20	News Coverage Analyst Revision Gap Up
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. CABR, DARE, MBRX, FNCH, and ASBP

How does SciSparc compare to Caring Brands?

Summary

How does SciSparc compare to Dare Bioscience?

Summary

How does SciSparc compare to Moleculin Biotech?

Summary

How does SciSparc compare to Finch Therapeutics Group?

Summary

How does SciSparc compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. CABR, DARE, MBRX, FNCH, and ASBP

How does SciSparc compare to Caring Brands?

Does the media refer more to CABR or SPRC?

Is CABR or SPRC more profitable?

Do insiders & institutionals hold more shares of CABR or SPRC?

Which has stronger earnings & valuation, CABR or SPRC?

Do analysts recommend CABR or SPRC?

Summary

How does SciSparc compare to Dare Bioscience?

Which has better earnings & valuation, DARE or SPRC?

Which has more risk and volatility, DARE or SPRC?

Do insiders and institutionals believe in DARE or SPRC?

Does the media prefer DARE or SPRC?

Do analysts recommend DARE or SPRC?

Is DARE or SPRC more profitable?

Summary

How does SciSparc compare to Moleculin Biotech?

Do insiders and institutionals hold more shares of SPRC or MBRX?

Do analysts recommend SPRC or MBRX?

Does the media favor SPRC or MBRX?

Is SPRC or MBRX more profitable?

Which has stronger valuation & earnings, SPRC or MBRX?

Which has more risk and volatility, SPRC or MBRX?

Summary

How does SciSparc compare to Finch Therapeutics Group?

Which has more risk and volatility, SPRC or FNCH?

Do analysts prefer SPRC or FNCH?

Which has preferable earnings & valuation, SPRC or FNCH?

Does the media refer more to SPRC or FNCH?

Is SPRC or FNCH more profitable?

Do institutionals & insiders hold more shares of SPRC or FNCH?

Summary

How does SciSparc compare to Aspire Biopharma?

Do insiders & institutionals believe in SPRC or ASBP?

Does the media favor SPRC or ASBP?

Which has preferable earnings and valuation, SPRC or ASBP?

Do analysts recommend SPRC or ASBP?

Which has more risk & volatility, SPRC or ASBP?

Is SPRC or ASBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools